KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright

Key Points

• Italian drugmaker Chiesi agreed to acquire KalVista for about $1.9 billion, offering $27.00 per share in cash — a deal driven partly by KalVista’s hereditary angioedema drug Ekterly and the primary catalyst behind the stock move.
• HC Wainwright downgraded KalVista from "buy" to "neutral" with a $27.00 price objective (implying roughly a 1.3% upside), and several other brokers have trimmed ratings leaving the consensus at a "Hold" with an average target of $30.60.
• Multiple shareholder law firms have launched fairness probes into the $27.00 offer and insiders have sold shares recently, raising legal risk and potential deal uncertainty that could delay or alter the acquisition.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) was downgraded by equities research analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a note issued to investors on Friday. They currently have a $27.00 price objective on the specialty pharmaceutical company's stock. HC Wainwright's target price suggests a potential upside of 1.28% from the stock's current price.

Several other analysts have also weighed in on the company. Wall Street Zen lowered KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 21st. JonesTrading downgraded KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday. Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Finally, Citizens Jmp cut shares of KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $30.60.

KalVista Pharmaceuticals Trading Down 0.0%

Shares of KALV stock opened at $26.66 on Friday. KalVista Pharmaceuticals has a fifty-two week low of $9.83 and a fifty-two week high of $26.76. The stock's fifty day moving average price is $18.45 and its two-hundred day moving average price is $15.72. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market cap of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40.

Insider Buying and Selling

In related news, CFO Brian Piekos sold 1,862 shares of the firm's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the transaction, the chief financial officer owned 18,150 shares in the company, valued at $366,993. This trade represents a 9.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider owned 138,983 shares in the company, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 263,969 shares of company stock valued at $4,536,178 over the last three months. Insiders own 4.30% of the company's stock.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in KalVista Pharmaceuticals by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company's stock worth $30,464,000 after purchasing an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. State Street Corp increased its stake in shares of KalVista Pharmaceuticals by 21.3% in the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company's stock valued at $30,874,000 after buying an additional 336,195 shares during the period. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company's stock valued at $30,524,000 after buying an additional 1,140,000 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company's stock worth $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi agreed to acquire KalVista for about $1.9 billion, offering $27.00 per share in cash — a clear catalyst that lifted KALV sharply on the announcement as investors priced in the takeover premium. Italian drugmaker Chiesi to buy KalVista for $1.9 billion
• Positive Sentiment: Multiple industry outlets detail Chiesi’s strategic rationale — bolstering its rare‑disease portfolio, notably KalVista’s hereditary angioedema drug Ekterly — which supports deal value and strategic fit. Chiesi to buy KalVista in $1.9B deal for rare disease drug
• Neutral Sentiment: Needham & Company reaffirmed a hold rating on KalVista, leaving formal analyst conviction mixed even after the deal announcement; this can temper further upside from buyout speculation. Needham & Company LLC rating note
• Negative Sentiment: Several brokers (JonesTrading, Leerink Partners, Citizens Jmp) downgraded KalVista from "strong‑buy" to "hold" following the deal — analyst downgrades can reduce follow‑through buying interest and liquidity. Zacks coverage of analyst actions
• Negative Sentiment: Multiple shareholder law firms have launched investigations and alerts questioning whether $27.00 per share is a fair price; potential litigation or a proxy fight could delay closing, create deal uncertainty, or prompt a revised offer. Ademi LLP shareholder alert
• Negative Sentiment: Additional law‑firm probes and class action announcements (Monteverde, Halper Sadeh and others) increase legal risk and could pressure sentiment until the deal closes or is resolved. Halper Sadeh investigation notice

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.